AR038557A1 - Composicion y metodos para determinar la susceptibilidad de un virus patogeno a los inhibidores de la proteasa - Google Patents
Composicion y metodos para determinar la susceptibilidad de un virus patogeno a los inhibidores de la proteasaInfo
- Publication number
- AR038557A1 AR038557A1 ARP030100520A ARP030100520A AR038557A1 AR 038557 A1 AR038557 A1 AR 038557A1 AR P030100520 A ARP030100520 A AR P030100520A AR P030100520 A ARP030100520 A AR P030100520A AR 038557 A1 AR038557 A1 AR 038557A1
- Authority
- AR
- Argentina
- Prior art keywords
- protease
- treatment
- hiv
- reduced susceptibility
- mutation
- Prior art date
Links
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 244000052769 pathogen Species 0.000 title 1
- 230000001717 pathogenic effect Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 5
- 108091005804 Peptidases Proteins 0.000 abstract 4
- 239000004365 Protease Substances 0.000 abstract 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 4
- 230000035772 mutation Effects 0.000 abstract 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 102220470514 Proteasome subunit beta type-3_V82A_mutation Human genes 0.000 abstract 1
- 102220564795 Protein Lines homolog 1_K20M_mutation Human genes 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102200089571 rs104893827 Human genes 0.000 abstract 1
- 102200024574 rs104894384 Human genes 0.000 abstract 1
- 102200037866 rs122454126 Human genes 0.000 abstract 1
- 102220080214 rs149830675 Human genes 0.000 abstract 1
- 102220278104 rs1554096640 Human genes 0.000 abstract 1
- 102220072394 rs200671745 Human genes 0.000 abstract 1
- 102220067568 rs202141764 Human genes 0.000 abstract 1
- 102220251169 rs368061837 Human genes 0.000 abstract 1
- 102220097967 rs876660873 Human genes 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente provee un enfoque para desarrollar un algoritmo para determinar la efectividad de drogas antivirales en base a un análisis comprehensivo de datos fenotípicos y genotípicos pareados guiados por cut-offs clínicos fenotípicos. En un aspecto, el algoritmo permite proveer a un paciente de un tratamiento efectivo. Ayuda a predecir si un individuo infectado responderá al tratamiento con un compuesto antiviral, permitiendo así un régimen de tratamiento efectivo a desarrollar sin someter al paciente a afectos colaterales innecesarios. Además, se ahorra considerablemente tiempo y dinero, evitando la administración de drogas no efectivas. Reivindicación 1: Un método para determinar si un VIH tiene una probabilidad incrementada de tener una susceptibilidad reducida a un tratamiento con un inhibidor de la proteasa, que comprende la detección en la proteasa de dicho VIH o en un ácido nucleico de dicho VIH que codifica la proteasa, de la presencia o la ausencia de una mutación asociada con la susceptibilidad reducida al tratamiento con dicho inhibidor de la proteasa en la posición del aminoácido 20, 33, 34, 43, 46, 48, 50, 54, 55, 58, 63, 66, 73, 74, 76, 79, 82, 84 u 89 de la secuencia de aminoácidos de dicha proteasa, donde la presencia de dicha mutación indica que el VIH tiene una probabilidad incrementada de tener una susceptibilidad reducida al tratamiento con el inhibidor de la proteasa, con la condición de que dicha mutación no sea K20M, K20R, M46I, M46L, I54L, I54T, I54V, L63P, V82A, V82F, V82T o I84V.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35717102P | 2002-02-15 | 2002-02-15 | |
| US35934202P | 2002-02-22 | 2002-02-22 | |
| US39237702P | 2002-06-26 | 2002-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038557A1 true AR038557A1 (es) | 2005-01-19 |
Family
ID=27761425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100520A AR038557A1 (es) | 2002-02-15 | 2003-02-17 | Composicion y metodos para determinar la susceptibilidad de un virus patogeno a los inhibidores de la proteasa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7384734B2 (es) |
| EP (1) | EP1483416B1 (es) |
| CN (1) | CN1646704A (es) |
| AR (1) | AR038557A1 (es) |
| AT (1) | ATE543915T1 (es) |
| AU (1) | AU2003211026A1 (es) |
| CA (1) | CA2476403C (es) |
| ES (1) | ES2381866T3 (es) |
| TW (1) | TW200303362A (es) |
| WO (1) | WO2003070700A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6869759B1 (en) | 1999-06-22 | 2005-03-22 | Virologic, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| US7138231B2 (en) | 2000-09-15 | 2006-11-21 | Monogram Biosciences, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| US7186506B1 (en) | 2000-06-12 | 2007-03-06 | Monogram Biosciences, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| US20030108857A1 (en) * | 2001-06-04 | 2003-06-12 | Parkin Neil T. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| US7384734B2 (en) | 2002-02-15 | 2008-06-10 | Monogram Biosciences, Inc. | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
| JP2006506967A (ja) | 2002-07-01 | 2006-03-02 | バイロロジック，インコーポレーテッド | プロテアーゼ阻害剤に対する病原性ウイルスの感受性を決定するための組成物および方法 |
| TW200411180A (en) | 2002-07-01 | 2004-07-01 | Virologic Inc | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
| US20050148523A1 (en) * | 2003-12-15 | 2005-07-07 | Colonno Richard J. | Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor |
| US20100070184A1 (en) * | 2006-01-19 | 2010-03-18 | Monogram Biosciences, Inc. | Method for determining resistance of hiv to protease inhibitor treatment |
| EP2121589A2 (en) * | 2006-12-18 | 2009-11-25 | University of Massachusetts | Crystal structures of hiv-1 protease inhibitors bound to hiv-1 protease |
| KR101459805B1 (ko) * | 2007-03-30 | 2014-11-07 | 9898 리미티드 | 천연 산물 개발을 위한 약제 플랫폼 기법 |
| EP2178512B1 (en) * | 2007-06-22 | 2011-03-09 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
| JP2010530888A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
| JP2010530889A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
| PT2178513E (pt) * | 2007-06-22 | 2011-05-31 | Bristol Myers Squibb Co | Composi??es em comprimido que cont?m atazanavir |
| US10480037B2 (en) | 2011-09-23 | 2019-11-19 | Laboratory Corporation Of America Holdings | Methods and systems for predicting HIV-1 coreceptor tropism |
| CN103215348B (zh) * | 2013-03-19 | 2015-06-03 | 浙江大学 | Hiv-1病毒蛋白酶抑制剂耐药突变检测试剂盒及方法 |
| JP7071976B2 (ja) * | 2016-11-28 | 2022-05-19 | コーニンクレッカ フィリップス エヌ ヴェ | 抗生物質感受性の分析的予測 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| DE68921034D1 (de) * | 1988-09-27 | 1995-03-23 | Dana Farber Cancer Inst Inc | Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält. |
| US5436131A (en) * | 1993-04-02 | 1995-07-25 | Merck & Co., Inc. | Color screening assay for identifying inhibitor resistant HIV protease mutants |
| US5766842A (en) * | 1994-09-16 | 1998-06-16 | Sepracor, Inc. | In vitro method for predicting the evolutionary response of a protein to a drug targeted thereagainst |
| US5837464A (en) * | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US6242187B1 (en) * | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US6103462A (en) * | 1998-05-29 | 2000-08-15 | Institut Pasteur | Rapid single-cycle assay for human immunodeficiency virus type-1 drug resistance |
| JP2003503004A (ja) | 1998-06-24 | 2003-01-28 | バイロロジック・インコーポレイテッド | ヌクレオチド逆転写酵素阻害剤抗レトロウイルス療法をモニターし、ｈｉｖ／ａｉｄｓの治療における治療決定をガイドする手段および方法 |
| US20030108857A1 (en) * | 2001-06-04 | 2003-06-12 | Parkin Neil T. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| BR0011939A (pt) | 1999-06-22 | 2002-03-12 | Virologic Inc | Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids |
| US7138231B2 (en) | 2000-09-15 | 2006-11-21 | Monogram Biosciences, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| CA2422815A1 (en) | 2000-09-15 | 2002-03-21 | Virologic, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
| WO2002099387A2 (en) | 2001-06-04 | 2002-12-12 | Virologic, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
| US7384734B2 (en) | 2002-02-15 | 2008-06-10 | Monogram Biosciences, Inc. | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
| TW200411180A (en) | 2002-07-01 | 2004-07-01 | Virologic Inc | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
| JP2006506967A (ja) | 2002-07-01 | 2006-03-02 | バイロロジック，インコーポレーテッド | プロテアーゼ阻害剤に対する病原性ウイルスの感受性を決定するための組成物および方法 |
-
2003
- 2003-02-13 US US10/367,223 patent/US7384734B2/en not_active Expired - Fee Related
- 2003-02-14 CA CA2476403A patent/CA2476403C/en not_active Expired - Fee Related
- 2003-02-14 AU AU2003211026A patent/AU2003211026A1/en not_active Abandoned
- 2003-02-14 AT AT03742733T patent/ATE543915T1/de active
- 2003-02-14 EP EP03742733A patent/EP1483416B1/en not_active Expired - Lifetime
- 2003-02-14 TW TW092103100A patent/TW200303362A/zh unknown
- 2003-02-14 CN CN03808382.5A patent/CN1646704A/zh active Pending
- 2003-02-14 WO PCT/US2003/004362 patent/WO2003070700A2/en not_active Ceased
- 2003-02-14 ES ES03742733T patent/ES2381866T3/es not_active Expired - Lifetime
- 2003-02-17 AR ARP030100520A patent/AR038557A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1483416B1 (en) | 2012-02-01 |
| ATE543915T1 (de) | 2012-02-15 |
| CA2476403A1 (en) | 2003-08-28 |
| US7384734B2 (en) | 2008-06-10 |
| ES2381866T3 (es) | 2012-06-01 |
| AU2003211026A1 (en) | 2003-09-09 |
| EP1483416A2 (en) | 2004-12-08 |
| US20040224307A1 (en) | 2004-11-11 |
| WO2003070700A3 (en) | 2004-02-26 |
| TW200303362A (en) | 2003-09-01 |
| CA2476403C (en) | 2012-09-11 |
| WO2003070700A2 (en) | 2003-08-28 |
| CN1646704A (zh) | 2005-07-27 |
| EP1483416A4 (en) | 2006-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038557A1 (es) | Composicion y metodos para determinar la susceptibilidad de un virus patogeno a los inhibidores de la proteasa | |
| Hermisson et al. | Soft sweeps and beyond: understanding the patterns and probabilities of selection footprints under rapid adaptation | |
| Couzin-Frankel | Antiviral pills could change pandemic’s course | |
| Softic et al. | Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor alisporivir (Debio 025) | |
| Asselah et al. | Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis | |
| Law et al. | Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 | |
| Aguilar et al. | Iquitos virus: a novel reassortant Orthobunyavirus associated with human illness in Peru | |
| Borrmann et al. | Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast | |
| Shilaih et al. | Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals | |
| Economides et al. | Concomitant use of direct‐acting antivirals and chemotherapy in hepatitis C virus‐infected patients with cancer | |
| Thase et al. | Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression | |
| ATE344029T1 (de) | Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern | |
| He et al. | Systematic review with meta‐analysis: effectiveness of direct‐acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma | |
| AR040370A1 (es) | Composiciones y metodos para determinar la susceptibilidad de un virus patogenico a los inhibidores de proteasa | |
| Mokrousov et al. | Efficient discrimination within a Corynebacterium diphtheriae epidemic clonal group by a novel macroarray-based method | |
| AR040371A1 (es) | Composiciones y metodos para determinar la susceptibilidad de un virus patogeno a los inhibidores de proteasa | |
| Sulkowski | HCV‐HIV co‐infected patients: no longer a ‘special’population? | |
| Schulte et al. | Levocarnitine for pegaspargase‐induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia | |
| Pott-Junior et al. | Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial | |
| BR0011939A (pt) | Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids | |
| Boucau et al. | Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells | |
| BR0317539A (pt) | Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais | |
| Van De et al. | Dirofilaria repens in Vietnam: detection of 10 eye and subcutaneous tissue infection cases identified by morphology and molecular methods | |
| Rosado-Quiñones et al. | Novel hydrazone compounds with broad-spectrum antiplasmodial activity and synergistic interactions with antimalarial drugs | |
| Martin et al. | Hepatitis C virus infection among people who inject drugs in Bangkok, Thailand, 2005–2010 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |